Bacterial vaginosis: Review of treatment options and potential clinical indications for therapy

Clinical Infectious Diseases

Volumn 28, Issue 1 SUPPL., 1999, Pages

  Joesoef, M R ^a   Schmid, G P ^b   Hillier, S L ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; METRONIDAZOLE;

ANAEROBIC BACTERIUM; ARTICLE; DIAGNOSTIC APPROACH ROUTE; FEMALE; GARDNERELLA VAGINALIS; GRAM STAINING; HIGH RISK POPULATION; HUMAN; INTRAVAGINAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PREGNANCY; PRIORITY JOURNAL; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; VAGINITIS;

EID: 0033045210     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514725     Document Type: Article

References (60)

1. Eschenbach DA, Hillier SL, Critchlow C, Steven C, DeRouen T, Holmes KK. Diagnosis and clinical manifestation of bacterial vaginosis. Am J Obstet Gynecol 1988;158:819-28.
2. Thomason JL, Gelbart SM, Wilcoski LM, Peterson AK, Jilly BJH. Proline aminopeptidase activity as a rapid diagnostic test to confirm bacterial vaginosis. Obstet Gynecol 1988;71:607-11.
3. 2-producing lactobacilli, and bacterial vaginosis in pregnant women. Clin Infect Dis 1993;16(suppl 4):S273-81.
4. Barbone F, Austin H, Louv WC, Alexander WJ. A follow-up study of methods of contraception, sexual activity, and rates of trichomoniasis, candidiasis, and bacterial vaginosis. Am J Obstet Gynecol 1990;163: 510-4.
5. Avonts D, Sercu M, Heyerick P, Vandermeeren I, Meheus A, Piot P. Incidence of uncomplicated genital infections in women using oral contraception or an intrauterine device: a prospective study. Sex Transm Dis 1990;17:23-9.
6. Hawes SE, Hillier SL, Benedetti J, et al. Hydrogen peroxide -producing lactobacilli and acquisition of vaginal infections. J Infect Dis 1996;174: 1058-63.
7. Joesoef MR, Schmid GP. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clin Infect Dis 1995; 20(suppl 1):S72-9.
8. Amsel R, Totten PA, Spiegel CA, Chen KCS, Eschenbach DA. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983;74:14-22.
9. Dunkelberg WE. Diagnosis of Haemophilus vaginalis vaginitis by gram-stained smears. Am J Obstet Gynecol 1965;91:998-1000.
10. Spiegel CA, Amsel R, Holmes KK. Diagnosis of bacterial vaginosis by direct gram stain of vaginal fluid. J Clin Microbiol 1983;18:170-7.
11. Nugent RP, Krohn MA, Hillier SL. The reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991;29:297-301.
12. Joesoef MR, Hillier SL, Josodiwondo S, Linnan M. Reproducibility of a scoring system for gram stain diagnosis of bacterial vaginosis. J Clin Microbiol 1991;29:1730-1.
13. Schwebke JR, Hillier SL, Sobel JD, McGregor JA, Sweet RL. Validity of the vaginal gram stain for the diagnosis of bacterial vaginosis. Obstet Gynecol 1996;88:573-6.
14. Larsson P-G. Treatment of bacterial vaginosis. Int J STD AIDS 1992;3: 239-47.
15. Rein MF, Holmes KK. Nonspecific vaginitis, vulvovaginal candidiasis and trichomoniasis. Current Clin Top Infect Dis 1983:292-304.
16. McCarthy LR, Mickelsen P, Smith E. Antibiotic susceptibility of Haemophilus vaginalis (Corynebacterium vaginale) to 21 antibiotics. Antimicrob Agents Chemother 1979;16:186-9.
17. Hillier S, Krohn MA, Watts DH, Wolner-Hanssen P, Eschenbach D. Microbiologic efficacy of intravaginal clindamycin cream for the treatment of bacterial vaginosis. Obstet Gynecol 1990;76:407-13.
18. Stein GE, Christensen SL, Mummaw NL, Soper DE. Placebo-controlled trial of intravaginal clindamycin 2% cream for the treatment of bacterial vaginosis. Ann Pharmacother 1993;27:1343-5.
19. Hillier SL, Lipinski C, Briselden AM, Eschenbach DA. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis. Obstet Gynecol 1993;81:963-7.
20. Livengood CH 3rd, McGregor JA, Soper DE, Newton E, Thomason JL. Bacterial vaginosis: efficacy and safety of intravaginal metronidazole treatment [see comments]. Am J Obstet Gynecol 1994;170:759-64.
21. Fischbach F, Petersen EE, Weissenbacher ER, Martius J, Hosmann J, Mayer H. Efficacy of clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis. Obstet Gynecol 1993;82: 405-10.
22. Andres FJ, Parker R, Hosein I, Benrubi GI. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial. South Med J 1992;85:1077-80.
23. Schmitt C, Sobel JD, Meriwether C. Bacterial vaginosis: treatment with clindamycin cream versus oral metronidazole. Obstet Gynecol 1992; 79:1020-3.
24. Ferris DC, Litaker MS, Woodward L, Mathis D, Hendrich J. Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. J Fam Pract 1995;41: 443-9.
25. Curatek Pharmaceuticals. MetroGel-Vaginal (metronidazole vaginal gel): effective intravaginal therapy for bacterial vaginosis. A clinical monograph. Elk Grove Village, IL: Curatek Pharmaceuticals, 1996:17-8.
26. McGregor JA, Hillier SL, Eschenbach DA, et al. Efficacy of Metrogel-Vaginal versus oral metronidazole for treatment of bacterial vaginosis: a randomized, single-blind parallel comparison [abstract no 3]. Presented at the 11th Meeting of the International Society of Sexually Transmitted Diseases Research (New Orleans). 1995.
27. Greaves WL, Chungafung J, Morris B, Haile A, Townsend JL. Clindamycin versus metronidazole in the treatment of bacterial vaginosis. Obstet Gynecol 1988;72:799-802.
28. Cunningham FE, Kraus DM, Brubaker L, Fischer JH. Pharmacokinetics of intravaginal metronidazole gel. J Clin Pharmacol 1994;34:1060-5.
29. Borin MT, Powley GW, Tackwell KR, Batts DH. Absorption of clindamycin after intravaginal application of clindamycin phosphate 2% cream. J Antimicrob Chemother 1995;35:833-41.
30. Vaginal infections. Ropert Starch Worldwide, 1996:1-24.
31. Faro S, Phillips LE, Martens MG. Perspectives on the bacteriology of postoperative obstetric-gynecologic infections. Am J Obstet Gynecol 1988;158(suppl):694-700.
32. Hillier SL, Martius J, Krohn MA, Kiviat NB, Holmes KK, Eschenbach DA. Case-control study of chorioamnionic infection and chorioamnionitis in prematurity. N Engl J Med 1988;319:972-5.
33. Watts D, Krohn M, Hillier S, Eschenbach D. Bacterial vaginosis as a risk factor for postcesarean endometritis. Obstet Gynecol 1990;75:52-8.
34. Gravett MG, Nelson HP, DeRouen T, Critchlow C, Eschenbach DA, Holmes KK. Independent associations of bacterial vaginosis and Chlamydia trachomatis infection with adverse pregnancy outcome. JAMA 1986;256:1899-903.
35. Graven MG, Hummel D, Eschenbach DA, Holmes KK. Preterm labor associated with subclinical amniotic fluid infection and with bacterial vaginosis. Obstet Gynecol 1986;67:229-37.
36. Newton ER, Prihoda TJ, Gibbs RS. A clinical and microbiologic analysis of risk factors for puerperal endometritis. Obstet Gynecol 1990;75: 402-6.
37. McGregor JA, French JI, Richter R, et al. Antenatal microbiologic and maternal risk factors associated with prematurity. Am J Obstel Gynecol 1990;163:1465-73.
38. Holmes KK, Chen KCS, Lipinski CM, Eschenbach DA. Vaginal redox potential in bacterial vaginosis (nonspecific vaginitis). J Infect Dis 1985; 152:379-82.
39. Briselden M, Moncla B, Stevens C, Hillier S. Sialidases (neuraminidases) in bacterial vaginosis and bacterial vaginosis - associated microflora. J Clin Microbiol 1992;30:663-6.
40. McGregor JA, French JI, Jones W, et al. Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream. Am J Obstet Gynecol 1994;170:1048;59.
41. Platz-Christensen JJ, Mattsby-Baltzer I, Thomsen P, Wiqvist N. Endotoxin and interleukin-1c in the cervical mucus and vaginal fluid of pregnant women with bacterial vaginosis. Am J Obstet Gynecol 1993;169: 1161-6.
42. Platz-Christensen JJ, Brandberg A, Wiqvist N. Increased prostaglandin concentrations in the cervical mucus of pregnant women with bacterial vaginosis. Prostaglandins 1992;43:133-4.
43. Centers for Disease Control and Prevention. 1993 Sexually transmitted diseases treatment guidelines. MMWR Morb Mortal Wkly Rep 1993; 42:27-46.
44. Morales WJ, Schom S, Albritton J. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. Am J Obstet Gynecol 1994; 171:345-9.
45. Hauth JC, Goldenberg RL, Andrews WW, DuBard MB, Copper RL. Mid-trimester treatment with metronidazole plus erythromycin reduces preterm delivery only in women with bacterial vaginosis [abstract]. Am J Obstet Gynecol 1995;172:253.
46. Joesoef MR, Hillier SL, Wiknjosastro G, et al. Intravaginal clindamycin treatment for bacterial vaginosis: effects on preterm delivery and low birth weight. Am J Obstet Gynecol 1995;173:1527-31.
47. McGregor JA, French JI, Seo K. Adjunctive clindamycin therapy for preterm labor: results of a double-blind, placebo-controlled trial. Am J Obstet Gynecol 1991;165:867-75.
48. McGregor JA, French JI, Parker R, et al. Prevention of premature birth by screening and treatment for common genital tract infections: results of a prospective controlled evaluation [see comments]. Am J Obstet Gynecol 1995;173:157-67.
49. McDonald HM, O'Loughlin JA, Vigneswaran R, et al. Metronidazole treatment of bacterial vaginosis in pregnancy and preterm birth: a randomized, placebo-controlled trial [abstract]. Presented at the Infectious Diseases Society Obstetrics and Gynecology Meeting (Beaver Creek, Colorado). 1996.
50. Krohn MA, Thwin SS, Rabe LK, Brown Z, Hillier SL. Vaginal colonization by Escherichia coli as a risk factor for very low birth weight delivery and other perinatal complications. J Infect Dis 1997;175: 606-10.
51. Burtin P, Taddio A, Ariburnu O, Einarson TR, Koren G. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol 1995;172: 525-9.
52. Schwebke JR. Metronidazole: utilization in the obstetric and gynecologic patient. Sex Transm Dis 1995;22:370-6.
53. Cantu JM, Garcia-Cruz D. Midline facial defect as a teratogenic effect of metronidazole. Birth Defects 1982;18:85-8.
54. Greenberg F. Possible metronidazole teratogenicity and clefting. Am J Med Genet 1985;22:825.
55. Struthers BJ. Metronidazole appears not to be a human tetratogen: review of literature. Infect Dis Obstet Gynecol 1997;5:326-35.
56. Hasselquist MB, Hillier S. Susceptibility of upper-genital-tract isolates from women with pelvic inflammatory disease to ampicillin, cefpodoxime, metronidazole, and doxycycline. Sex Transm Dis 1991;18: 146-9.
57. Vejtorp M, Bollerup AC, Vejtorp L, et al. Bacterial vaginosis: a double-blind randomized trial of the effect of treatment of the sexual partner. Br J Obstet Gynecol 1988;95:920-6.
58. Moi H, Erkkola R, Jerve F, et al. Should male consorts of women with bacterial vaginosis be treated? Genitourin Med 1989;65:263-8.
59. Mengel MB, Berg AO, Weaver CH, et al. The effectiveness of single-dose metronidazole therapy for patients and their partners with bacterial vaginosis. J Fam Pract 1989;28:163-71.
60. Larsson PG, Platz-Christensen JJ, Thejls H, Forsum U, Pahlson C. Incidence of pelvic inflammatory disease after first-trimester legal abortion in women with bacterial vaginosis after treatment with metronidazole: a double-blind, randomized study. Am J Obstet Gynecol 1992;166: 100-3.